<DOC>
	<DOCNO>NCT03071406</DOCNO>
	<brief_summary>The purpose study test effectiveness , safety , tolerability drug nivolumab plus ipilimumab without addition stereotactic body radiation therapy ( SBRT ) . Nivolumab antibody ( type human protein ) test see stimulate body 's immune system work tumor cell . This study test investigational use nivolumab .</brief_summary>
	<brief_title>Randomized Study Nivolumab+Ipilimumab+/- SBRT Metastatic Merkel Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>At least 18 year age Eastern Cooperative Oncology Group ( ECOG ) Performance Status le 2 Active disease measurable CT MRI Prior chemotherapy immunotherapy allow new persistent measurable site ( ) disease present . Prior radiation therapy allow active measurable disease previously treat radiation therapy . Must either recurrent Stage IV American Joint Committee Cancer ( AJCC ) ( 7th edition ) histologically confirm Merkel cell carcinoma least 2 distinct lesion order eligible . Must least 2 distinct lesion document complete physical examination image study within 4 week prior randomization . Imaging study must include diagnostic CT scan involve disease site know site resect disease brain magnetic resonance ( MRI ) CT ( brain CT allowable MRI contraindicate known history resect brain lesion ) . Tumor tissue core biopsy resect site disease must provide biomarker analysis . History Grade 3 toxicity use infliximab prior immunotherapy Patients brain metastasis . Active , know , suspect autoimmune disease . Potential participant type I diabetes mellitus , residual hypothyroidism due autoimmune thyroiditis require hormone replacement , skin disorder ( vitiligo , psoriasis , alopecia ) require systemic treatment permit enroll . Patients previous nonMerkel cell carcinoma malignancy exclude unless complete remission achieve least 3 year prior study entry additional therapy require anticipate required study period ( exception include limited , nonmelanoma/Merkel cell carcinoma skin cancer ; situ bladder cancer , situ gastric cancer , situ colon cancer ; situ cervical cancers/dysplasia ; breast carcinoma situ ) . A condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day randomization . Inhaled topical steroid permit absence active autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Merkel cell carcinoma ( MCC )</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Metastasis</keyword>
	<keyword>Stereotactic body radiation therapy ( SBRT )</keyword>
	<keyword>Immunology</keyword>
	<keyword>Antibody</keyword>
	<keyword>Nivolumab</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>Metastatic skin cancer</keyword>
	<keyword>Cutaneous</keyword>
</DOC>